EQ - Equillium Inc logo

Equillium Inc

EQ
Revenue grew 100% of years5Y
Compare EQ Hold

Equillium, Inc. develops therapeutics to treat severe autoimmune and inflammatory disorders. Its pipeline includes EQ504 for ulcerative colitis and lung inflammation, and EQ302, an oral bi-specific inhibitor for celiac disease, targeting high unmet needs.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$217today

Score Overview

1 Year
Scoreโ€”
Net Growth19.60%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trendโ€”
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth53.80%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendEvery year
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-35.92%
Net Trend38%
Net Income Consistency
Rev Growthโ€”
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Equillium Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. EQ does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 1.27โ€”
1 Year2025-10-22
$ 1.29-1.55%
5 Years2021-10-22
$ 5.86-78.33%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 18M$ 57M
2025-$ 22M$ 30M
2024$ 41M-$ 8M$ 22M
2023$ 36M-$ 13M$ 40M
2022$ 15M-$ 62M$ 71M
2021$ 0.00-$ 38M$ 80M
2020$ 0.00-$ 29M$ 82M
2019$ 0.00-$ 25M$ 53M
IPO2018$ 0.00-$ 13M$ 65M
EQ - Equillium Inc logo

Equillium Inc fundamental performance

Across Equillium Inc's full reported history, from 2018 to 2025, net income went from -$ 13M to -$ 22M. Revenue increased in 50% of the years measured; net income in 38%.

Membership

Explore EQ with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies